Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Fulcrum Therapeutics, Inc.FULC · Entity 5969 | Chief Medical Officer | January 19, 2022 | January 21, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Fulcrum Therapeutics, Inc.
Report date January 19, 2022 · Filed January 21, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.69 · Expires 2032-01-18 | Direct | 59,744 |
Reported balance
After 2022-01-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-01-19 · Grant · Acquired 59,744 · Balance 59,744 F1: This option was granted on January 19, 2022 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2022, subject to continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on January 19, 2022 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2022, subject to continued service.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Astria Therapeutics, Inc.
Report date January 23, 2026 · Filed January 23, 2026
Section 16 reporting ended · disclosed 2026-01-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.87 | Direct | 0 |
Reported balance
After 2026-01-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-23 · Disposition to issuer · Disposed 80,000 · Balance 0 F1: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.41 | Direct | 0 |
Reported balance
After 2026-01-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-23 · Disposition to issuer · Disposed 262,500 · Balance 0 F1: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 23, 2026 Filed Jan 23, 2026 16:35 UTC | Astria Therapeutics, Inc. ATXS · Entity 68888 | Disposition to issuerStock Option (Right to Buy) · Derivative | 262,500 | Not disclosed Strike: $6.41 | Not disclosed |
DisclosureSEC source: 0000905148-26-000323 · form4.xml · derivative · entry 2 Morabito Christopher · CIK 0001859284 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 262,500 shares Expires not disclosed F1 · price: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest. F1 · derivative.exercise_date: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest. F1 · derivative.expiration_date: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest. Read SEC document |
| January 23, 2026 Filed Jan 23, 2026 16:35 UTC | Astria Therapeutics, Inc. ATXS · Entity 68888 | Disposition to issuerStock Option (Right to Buy) · Derivative | 80,000 | Not disclosed Strike: $3.87 | Not disclosed |
DisclosureSEC source: 0000905148-26-000323 · form4.xml · derivative · entry 1 Morabito Christopher · CIK 0001859284 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 80,000 shares Expires not disclosed F1 · price: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest. F1 · derivative.exercise_date: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest. F1 · derivative.expiration_date: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest. Read SEC document |
| March 21, 2025 Filed Mar 25, 2025 16:05 UTC | Astria Therapeutics, Inc. ATXS · Entity 68888 | GrantStock Option (Right to Buy) · Derivative | 262,500 | $0.00 Strike: $6.41 | $0.00 |
DisclosureSEC source: 0001104659-25-027765 · tm2510055-1_4seq1.xml · derivative · entry 1 Morabito Christopher · CIK 0001859284 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 262,500 Underlying: Common Stock · 262,500 shares Expires 2035-03-20 F1 · derivative.exercise_date: This option was granted on March 21, 2025 and is subject to vesting over a four-year period, with 25% of the 262,500 shares underlying the option upon grant vesting on the first anniversary of February 13, 2025 and the remainder vesting over the ensuing three years in equal monthly installments. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 16:05 UTC | Astria Therapeutics, Inc. ATXS · Entity 68888 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $3.87 | $0.00 |
DisclosureSEC source: 0001104659-24-043092 · tm2410392-1_4seq1.xml · derivative · entry 3 Morabito Christopher · CIK 0001859284 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 10,000 shares Expires 2032-07-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on March 31, 2023. F3 · derivative.exercise_date: This option was granted on August 1, 2022, pursuant to the Issuer's 2022 Inducement Stock Incentive Plan and the terms and conditions of an award agreement covering the option grant. This option is subject to vesting over a four year period, with 25% of shares vested on the first anniversary of July 14, 2022, the reporting person's employment start date, and the remainder vesting over the ensuing three years at a rate of 2.0833% per month. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 16:05 UTC | Astria Therapeutics, Inc. ATXS · Entity 68888 | SaleCommon Stock | 10,000 | $13.59 | $135,939.00 |
DisclosureSEC source: 0001104659-24-043092 · tm2410392-1_4seq1.xml · nonDerivative · entry 2 Morabito Christopher · CIK 0001859284 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on March 31, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.37 to $13.76, inclusive. The reporting person undertakes to provide to Astria Therapeutics, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 16:05 UTC | Astria Therapeutics, Inc. ATXS · Entity 68888 | Exercise / conversionCommon Stock | 10,000 | $3.87 | $38,700.00 |
DisclosureSEC source: 0001104659-24-043092 · tm2410392-1_4seq1.xml · nonDerivative · entry 1 Morabito Christopher · CIK 0001859284 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on March 31, 2023. Read SEC document |
| February 08, 2024 Filed Feb 12, 2024 16:06 UTC | Astria Therapeutics, Inc. ATXS · Entity 68888 | GrantStock Option (Right to Buy) · Derivative | 175,000 | $0.00 Strike: $15.26 | $0.00 |
DisclosureSEC source: 0001104659-24-014618 · tm245876-6_4seq1.xml · derivative · entry 1 Morabito Christopher · CIK 0001859284 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2034-02-07 F1 · derivative.exercise_date: This option was granted on February 8, 2024 and is subject to vesting over a four-year period, with 25% of the 175,000 shares underlying the option upon grant vesting on the first anniversary of February 8, 2024 and the remainder vesting over the ensuing three years in equal monthly installments. Read SEC document |
| January 29, 2024 Filed Jan 30, 2024 17:03 UTC | Astria Therapeutics, Inc. ATXS · Entity 68888 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,200 | $0.00 Strike: $3.87 | $0.00 |
DisclosureSEC source: 0001104659-24-008327 · tm244587-1_4seq1.xml · derivative · entry 6 Morabito Christopher · CIK 0001859284 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 9,200 shares Expires 2032-07-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on March 31, 2023. F4 · derivative.exercise_date: The option was granted on August 1, 2022, pursuant to the Issuer's 2022 Inducement Stock Incentive Plan and the terms and conditions of an award agreement covering the option grant. This option is subject to vesting over a four year period, with 25% of shares vested on the first anniversary of July 14, 2022, the reporting person's employment start date, and the remainder vesting over the ensuing three years at a rate of 2.0833% per month. Read SEC document |
| January 29, 2024 Filed Jan 30, 2024 17:03 UTC | Astria Therapeutics, Inc. ATXS · Entity 68888 | SaleCommon Stock | 9,200 | $11.15 | $102,552.40 |
DisclosureSEC source: 0001104659-24-008327 · tm244587-1_4seq1.xml · nonDerivative · entry 4 Morabito Christopher · CIK 0001859284 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on March 31, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.00 to $11.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| January 29, 2024 Filed Jan 30, 2024 17:03 UTC | Astria Therapeutics, Inc. ATXS · Entity 68888 | Exercise / conversionCommon Stock | 9,200 | $3.87 | $35,604.00 |
DisclosureSEC source: 0001104659-24-008327 · tm244587-1_4seq1.xml · nonDerivative · entry 3 Morabito Christopher · CIK 0001859284 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on March 31, 2023. Read SEC document |
| January 26, 2024 Filed Jan 30, 2024 17:03 UTC | Astria Therapeutics, Inc. ATXS · Entity 68888 | Exercise / conversionStock Option (Right to Buy) · Derivative | 800 | $0.00 Strike: $3.87 | $0.00 |
DisclosureSEC source: 0001104659-24-008327 · tm244587-1_4seq1.xml · derivative · entry 5 Morabito Christopher · CIK 0001859284 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 99,200 Underlying: Common Stock · 800 shares Expires 2032-07-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on March 31, 2023. F4 · derivative.exercise_date: The option was granted on August 1, 2022, pursuant to the Issuer's 2022 Inducement Stock Incentive Plan and the terms and conditions of an award agreement covering the option grant. This option is subject to vesting over a four year period, with 25% of shares vested on the first anniversary of July 14, 2022, the reporting person's employment start date, and the remainder vesting over the ensuing three years at a rate of 2.0833% per month. Read SEC document |
| January 26, 2024 Filed Jan 30, 2024 17:03 UTC | Astria Therapeutics, Inc. ATXS · Entity 68888 | SaleCommon Stock | 800 | $11.02 | $8,812.00 |
DisclosureSEC source: 0001104659-24-008327 · tm244587-1_4seq1.xml · nonDerivative · entry 2 Morabito Christopher · CIK 0001859284 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on March 31, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.00 to $11.02, inclusive. The reporting person undertakes to provide to Astria Therapeutics, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| January 26, 2024 Filed Jan 30, 2024 17:03 UTC | Astria Therapeutics, Inc. ATXS · Entity 68888 | Exercise / conversionCommon Stock | 800 | $3.87 | $3,096.00 |
DisclosureSEC source: 0001104659-24-008327 · tm244587-1_4seq1.xml · nonDerivative · entry 1 Morabito Christopher · CIK 0001859284 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on March 31, 2023. Read SEC document |
| June 02, 2023 Filed Jun 6, 2023 08:04 UTC | Astria Therapeutics, Inc. ATXS · Entity 68888 | GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $13.36 | $0.00 |
DisclosureSEC source: 0001104659-23-068337 · tm2317752-4_4seq1.xml · derivative · entry 1 Morabito Christopher · CIK 0001859284 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2033-01-31 F1 · date: This option was by granted effective as of February 1, 2023, subject to stockholder approval of an amendment to Astria Therapeutics, Inc.'s (the "Company") Amended and Restated 2015 Stock Incentive Plan to increase the number of shares available for issuance thereunder by 4,300,000 (the "Stock Plan Amendment Proposal"). The Company's stockholders approved the Stock Plan Amendment Proposal on June 2, 2023. F2 · derivative.exercise_date: This option was granted on February 1, 2023 and is subject to vesting over a four-year period, with 25% of the 90,000 shares underlying the option upon grant vesting on the first anniversary of February 1, 2023 and the remainder vesting over the ensuing three years in equal monthly installments. Read SEC document |
| August 01, 2022 Filed Aug 2, 2022 08:51 UTC | Astria Therapeutics, Inc. ATXS · Entity 68888 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $3.87 | $0.00 |
DisclosureSEC source: 0001104659-22-084988 · tm2222284-1_4seq1.xml · derivative · entry 1 Morabito Christopher · CIK 0001859284 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-07-31 F1 · derivative.exercise_date: The option was granted on August 1, 2022, pursuant to the Astria Therapeutics, Inc. 2022 Inducement Stock Incentive Plan and the terms and conditions of an award agreement covering the option grant. This option is subject to vesting over a four year period, with 25% of shares vesting on the first anniversary of July 14, 2022, the reporting person's employment start date, and the remainder vesting over the ensuing three years at a rate of 2.0833% per month. Read SEC document |
| January 19, 2022 Filed Jan 21, 2022 21:15 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 59,744 | $0.00 Strike: $12.69 | $0.00 |
DisclosureSEC source: 0000899243-22-002878 · doc4.xml · derivative · entry 1 Morabito Christopher · CIK 0001859284 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,744 Underlying: Common Stock · 59,744 shares Expires 2032-01-18 F1 · derivative.exercise_date: This option was granted on January 19, 2022 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2022, subject to continued service. Read SEC document |
| June 28, 2021 Filed Jun 29, 2021 20:16 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | PurchaseCommon Stock | 1,100 | $9.16 | $10,076.00 |
DisclosureSEC source: 0000899243-21-026557 · doc4.xml · nonDerivative · entry 1 Morabito Christopher · CIK 0001859284 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,100 Read SEC document |
| May 10, 2021 Filed May 12, 2021 20:30 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 163,000 | $0.00 Strike: $10.01 | $0.00 |
DisclosureSEC source: 0000899243-21-019264 · doc4.xml · derivative · entry 1 Morabito Christopher · CIK 0001859284 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,000 Underlying: Common Stock · 163,000 shares Expires 2031-05-09 F1 · derivative.exercise_date: This option was granted on May 10, 2021 and is scheduled to vest 25% on the first anniversary of the vesting commencement date of May 10, 2021. The remainder of the shares underlying the grant shall vest in equal quarterly installments over the following three years until the fourth anniversary of the vesting commencement date, subject to continued service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.